NeuroClues, a Belgian medical technology startup, has secured a €5 million Series A funding round to accelerate the European and U.S. deployment of its eye-tracking diagnostic device, described as a "stethoscope for the brain." The investment was led by the venture capital firm White Fund, with participation from existing investors Invest.BW, Sambrinvest, and private backers.
Founded in 2019 by CEO Antoine Pouppez and CTO Pierre Daye, NeuroClues has developed a portable, lightweight device that tracks microscopic eye movements—at a precision of 0.1 degrees—using an infrared camera and proprietary algorithms. The system is designed to assist neurologists in the early detection and monitoring of neurological disorders such as Parkinson's disease, Alzheimer's, multiple sclerosis, and strokes by analyzing oculomotor biomarkers.
The new capital will primarily fund clinical validation studies and regulatory approvals, including the CE mark in Europe and FDA clearance in the U.S. The company plans to initiate pilot projects with hospital networks in both regions. NeuroClues has already conducted studies with over 500 patients across European hospitals, including collaborations with the Erasme Hospital in Brussels and the University Hospital of Liège.
CEO Antoine Pouppez emphasized the device's potential to transform neurological practice: "Just as the stethoscope became fundamental for cardiologists, we aim to provide neurologists with an objective, quantitative tool for daily use." The technology aims to address the current reliance on subjective clinical assessments, enabling earlier intervention and more precise tracking of disease progression.
With the funding, NeuroClues also intends to expand its team, particularly in commercial and clinical operations. The startup previously raised €2.5 million in seed funding, bringing its total raised to €7.5 million. Its progress reflects growing investor interest in digital biomarkers and AI-driven diagnostic tools for neurology.